Guess what folks Bristol-Myers Squibb's Daklinza (daclatasvir) with Sovaldi(sofosbuvir for HCV genotype 3 has been approved by FDA. Yes, I'm excited to share this wonderful news and hopefully the cost won't be like Harvoni, but who am I kidding.
Daklinza, where do they come up with these names, is for those with chronic HCV with genotype 3. Some HCV patients with cirrhosis can take 60mg of Daklinza with Sovaldi (sofosbuvir) 400mg for 12 weeks.
Daklinza has a serious risk of symptomatic bradycardia when coadministerd with sofosbuvir and amiodarone.
The most common treatment related adverse events (AEs) 5% had headache, 14% fatigue, 8% nausea and 5% diarrhea.
Please see full important safety information.
Genotype 3 overview, 12% of chronic HCV patients in the US and is the 2nd most common Hepatitis C genotype globally after genotype 1. It is said Hep C genotype 3 is one of the most difficult but you can do it as so many others.
Please visit SoulofHealing.org, non profit, 501(c)(3) for our patient assistance programs. If you have been denied by insurance or you do not have insurance please visit SunnyPharma.info to get generic Sovaldi($695), Harvoni($1495), Epclusa($2195) and Daklinza($695). All prices are based upon 12 weeks and 84 tablets. Verified by American doctors and nurses.
No comments:
Post a Comment